- Home
- Asset Class
- Sector
- Latest
- Author
- Street Notes
- TheStreet
- Switch to
- Premium Tools
- Real Money
- Real Money Pro
- Action Alerts PLUS
- Stocks Under $10
- Breakout Stocks
- Options Profits
Latest Commentary
Real Money: Independent market insight from a veteran team of trusted Wall Street pros.
• Up-to-the-minute reports on market activity
• Actionable trade ideas
• Up-to-the-minute reports on market activity
• Actionable trade ideas
Latest Strategies
Real Money Pro: Professional tools and specific trade ideas for active investors.
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
Latest Alert
May 17, 2013 | 06:41 PM EDT
We plan to continue building up our financial and technology positions over the coming weeks. FULL ALERT »
Action Alerts PLUS: Jim Cramer and Stephanie Link actively manage a real money portfolio for Jim's charitable trust.
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
Latest Alert
May 17, 2013 | 04:34 PM EDT
We used the strength this week to take some profits in three model portfolio positions, and we added to two other holdings. FULL ALERT »
Stocks Under $10: David Peltier manages a portfolio of affordable stocks with huge upside potential.
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
Latest Alert
May 17, 2013 | 10:07 AM EDT
There is some news on three of our model portfolio holdings. Here are the highlights. FULL ALERT »
Breakout Stocks: Bryan Ashenberg, CFA, manages a portfolio of small and mid-cap stocks with high growth potential.
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
Latest Commentary
Options Profits: Day in and day out, our team of professional options traders search for inventive plays for trading spikes in market activity, emerging trends, and breaking news and events. These veterans reveal all their charts and technical data — delivering daily strategies and insightful commentary written specifically for the options trader plus 40 options trade ideas per week!
Pfizer Inc (PFE)
PFE (NYSE:Drugs)
$28.96
-0.29
-0.99%
Today's Range: 28.83 - 29.37 |
PFE Avg Daily Volume: 32,123,300
| Last Update: 05/17/13 - 4:00 PM EDT |
| Volume: 37,642,372 |
| YTD Performance: 15.47% |
| Open: $29.21 |
| Previous Close: $29.25 |
| 52 Week Range: $21.40 - $31.15 |
| Oustanding Shares: 7,093,223,330 |
| Market Cap: 207,476,782,403 |
Analysts Ratings
| Historical Rec | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago |
|---|---|---|---|---|
| Strong Buy | 12 | 12 | 12 | 12 |
| Moderate Buy | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.34 | 1.34 | 1.34 | 1.34 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $0.57 | $0.55 | $2.21 | $2.35 |
| Number of Analysts | 8 | 7 | 9 | 10 |
| High Estimate | $0.58 | $0.57 | $2.25 | $2.45 |
| Low Estimate | $0.55 | $0.53 | $2.16 | $2.19 |
| Prior Year | $0.62 | $0.53 | $2.19 | $2.21 |
| Growth Rate (Year over Year) | -8.27% | 4.04% | 0.91% | 6.33% |
SeekingAlpha: Shades Of 1999 http://t.co/0KNjNkQbGu $AAPL $BMY $PBR $BP $CAT $CCL $CHK $COP $CRM $DNKN $GPS $KSS $M $PFE $SHLD $SXL $TIVO
10 minutes ago from Seeking Alpha
10 minutes ago from Seeking Alpha
AndyBiotech: @BloombergNow on Inhalable DrugDelivery Technology: ‘Love Hormone’ Promises Safer Births After Pfizer Flop http://t.co/8PiWhX5njQ $PFE $MNKD
1 hour ago from Tweet Button
1 hour ago from Tweet Button
eagledrc: Instead of whining about #Obamacare, make money off of it. That's the #American way. $MDSO $PFE $MMM $JNJ
6 hours ago from Twitter for iPhone
6 hours ago from Twitter for iPhone
w_pat_tc: WO2013068874A1 Antibody-drug Conjugates $PFE #A61K #A61K47 http://t.co/1K4X2uC104
20 hours ago from TwittlyDumb
20 hours ago from TwittlyDumb
w_pat_tc: WO2013068875A1 2-thiopyrimidinones $PFE #C07D #C07D239 http://t.co/gykTBgmjTo
20 hours ago from TwittlyDumb
20 hours ago from TwittlyDumb
w_pat_tc: WO2013068879A2 Infant Formula With High Sn-2 Palmitate And Oligofructose $PFE #A23L #A23L1 http://t.co/BZiBrfj7kw
20 hours ago from TwittlyDumb
20 hours ago from TwittlyDumb
w_pat_tc: WO2013068902A1 Methods Of Treating Inflammatory Disorders Using Anti-m-csf Antibodies $PFE #C07K #C07K16 http://t.co/jQoKqJK8m8
21 hours ago from TwittlyDumb
21 hours ago from TwittlyDumb
w_pat_tc: WO2013068909A1 ... $PFE #A61K #A61K31 http://t.co/Y99Xv6hinu
21 hours ago from TwittlyDumb
21 hours ago from TwittlyDumb
demycolton: RT @FiercePharma: Check out our Top 10 #cardio drugs of 2012, including #Lipitor, #Diovan and #Zetia. http://t.co/tDu8ksXsv7 $NVS $PFE $MRK #pharma
1 day ago from HootSuite
1 day ago from HootSuite
MolekuleBio: Angiogenesis inhibitors are live & well. Will be key focus @ #ASCO2013 look for noteworthy $REGN $SNY & $PFE molecules. #MolekuleInsight
1 day ago from web
1 day ago from web
Here are seven reasons why.
The Advance Runs Out of Steam Real Money Pro($)
A move below 1575 on the S&P 500 would be a signal to go short.
Focusing on near-term drug stock earnings is the wrong move.
May 01, 2013 | 7:32 AM EDT
PFE earnings estimates were reduced to reflect the impact of FX, said UBS.
It’s the only thing that explains today’s action.
These name capitalize on the trend of spending on our pets, which has become recession proof.
Plenty of leadership remains in the health care sector and there’s reason to see further potential.
Real Money Quick Links
Our Tweets
BROKERAGE PARTNERS
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
© 2013 TheStreet, Inc. All rights reserved.